Skip to Main Content

Paper Details

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Cancer Cell
21
2023
Circulating tumor, Circulating tumor DNA, HER2, HER2-negative breast cancer, HR, NAC, TNBC, breast cancer, cancer, circulating tumor DNA, ctDNA, early-stage, hormone receptor, patients, triple-negative breast cancer, tumor, tumor mRNA
Author NameAffiliation
Christina YauUniversity of California san francisco
Christina YauUniversity of California san francisco
Denise M WolfUniversity of California san francisco
Minetta C LiuInc., USA Mayo Clinic
Claudine IsaacsGeorgetown University
Rita NandaUniversity of Chicago
William F SymmansUniversity of Texas MD Anderson Cancer Center
Laura J Van't VeerUniversity of California san francisco
  • 1 - 8

Datasets

Release 1.2